Home » Thought Leadership

Thought Leadership

Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 124 posts
Is the Pricing Discount for NRDL Inclusion Worth it? NRDL Commercial Impact Assessment
July 6, 2021 | Blogs

Is the Pricing Discount for Chinese NRDL Inclusion Worth it? NRDL Commercial Impact Assessment

CBPartners Asia Pacific Center of Excellence team have analyzed the dynamics for drug products listed on China’s 2017 NRDL, and subsequent 2018 sales data, to better understand the commercial opportunity within China. Explore the research here.

June 17, 2021 | Infographics

KYMRIAH and TRELEGY Become the First Drugs to Undergo Japan’s New CEA System

What can be learned from the first use of Japan's new Cost-Effectiveness Assessment (CEA) system? Read CBPartners' infographic here.

The-Medical Fund Bill Poland Cover Image
June 2, 2021 | Blogs

Poland’s Medical Fund Bill to Improve Access to Oncology Drugs

The recently introduced Medical Fund Bill has potential to improve access to novel therapies applying for reimbursement in Poland, however, it is yet to be seen how the criteria for inclusion in the Fund’s list are clarified locally and whether a broader scope of therapies will be eligible for the scheme to deem the market more attractive for submissions.

Novel Combinations Double the Trouble
May 25, 2021 | Blogs

Novel Combinations: Double the Trouble

Launching a novel combination therapy provides a unique set of challenges and opportunities when seeking to achieve positive pricing and access outcomes. In this article, CBPartners reviewed the pricing and access outcomes from prior novel immuno-oncology combinations and have developed considerations for manufacturers developing strategies for their future pipeline.

CBPartners' Pharma Take-Away: AMARIN's VASCEPA patent loss: is it obvious(ness)?
May 20, 2021 | Podcasts

Opportunities and Barriers for Biosimilar Uptake in the USA

In the first of a multi-part biosimilar podcast series, CBPartners Healthcare Consultants are joined by special guest Dr. Bhavesh Shah, Senior Director of Pharmacy Strategy at Boston Medical Center, to explore the evolving biosimilar landscape in the USA.